| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PNPBP.2013.09.006 |
| P698 | PubMed publication ID | 24056287 |
| P50 | author | Kyoung-Sae Na | Q47817012 |
| P2093 | author name string | Ji Sung Lee | |
| Han-Yong Jung | |||
| Kang Joon Lee | |||
| Young Sung Cho | |||
| P921 | main subject | major depressive disorder | Q42844 |
| patient | Q181600 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 79-85 | |
| P577 | publication date | 2013-09-20 | |
| P1433 | published in | Progress in Neuro-Psychopharmacology & Biological Psychiatry | Q15616665 |
| P1476 | title | Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis | |
| P478 | volume | 48 |
| Q58736541 | Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo |
| Q33930731 | Antidepressant treatment response is modulated by genetic and environmental factors and their interactions |
| Q38637748 | Aspirin and incident depressive symptoms: A longitudinal cohort study over 8 years |
| Q38637621 | Backing into the future: pharmacological approaches to the management of resistant depression |
| Q26782993 | Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review |
| Q38654802 | Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. |
| Q34374437 | Blood levels of S-100 calcium-binding protein B, high-sensitivity C-reactive protein, and interleukin-6 for changes in depressive symptom severity after coronary artery bypass grafting: prospective cohort nested within a randomized, controlled trial |
| Q92862577 | COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders |
| Q37197216 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments |
| Q48018632 | Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial |
| Q26782997 | Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics |
| Q38709043 | Chronic peripheral inflammation, hippocampal neurogenesis, and behavior. |
| Q37676446 | Common mechanisms of pain and depression: are antidepressants also analgesics? |
| Q92897501 | Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, and New Directions |
| Q38476909 | Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. |
| Q38192667 | Fresh approaches to antidepressant drug discovery |
| Q36770623 | Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. |
| Q42322115 | High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib |
| Q42378870 | Immuno-psychiatry: an agenda for clinical practice and innovative research |
| Q33721031 | Immunological aspects of the treatment of depression and schizophrenia |
| Q38997609 | Increased levels of 5HT2A receptor mRNA expression in peripheral blood mononuclear cells of patients with major depression: correlations with severity and duration of illness. |
| Q31141746 | Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications |
| Q36023793 | Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes |
| Q37310528 | Inflammation in Depression and the Potential for Anti-Inflammatory Treatment |
| Q47560028 | Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder |
| Q38859380 | Integrating neuroimmune systems in the neurobiology of depression. |
| Q89537324 | Management of Treatment-Resistant Depression: Challenges and Strategies |
| Q39063138 | Managing epilepsy-associated depression: Serotonin enhancers or serotonin producers? |
| Q42738765 | Markers of inflammation in schizophrenia: association vs. causation |
| Q47645248 | Metabolic and inflammatory markers: associations with individual depressive symptoms |
| Q47140966 | Modulating Neuroinflammation to Treat Neuropsychiatric Disorders |
| Q90264439 | Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders |
| Q48071831 | Neuroscience, mental health and the immune system: overcoming the brain-mind-body trichotomy. |
| Q38313116 | New hypothesis and treatment targets of depression: an integrated view of key findings |
| Q38317241 | Novel investigational drugs targeting IL-6 signaling for the treatment of depression |
| Q58575504 | Old Friends, immunoregulation, and stress resilience |
| Q47556460 | Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation |
| Q26798241 | Pharmacological approaches to the challenge of treatment-resistant depression |
| Q39183229 | Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets. |
| Q33655590 | Physical Activity Modulates Common Neuroplasticity Substrates in Major Depressive and Bipolar Disorder |
| Q40826810 | Recovery from major depressive disorder episode after non-pharmacological treatment is associated with normalized cytokine levels |
| Q57134994 | Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis |
| Q38885617 | Role of Inflammation in Suicide: From Mechanisms to Treatment |
| Q92298709 | Safety evaluation and protective effects of ethanolic extract from maca (Lepidium meyenii Walp.) against corticosterone and H2O2 induced neurotoxicity |
| Q36063627 | Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia |
| Q30248903 | The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health |
| Q57820177 | The Neuroinflammation Perspective of Depression: Reuniting the Outstanding Mechanisms of the Pathophysiology |
| Q64892118 | The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. |
| Q92252661 | The gut microbiome in psychiatry: A primer for clinicians |
| Q38494723 | The link between depression and diabetes: the search for shared mechanisms |
| Q38828405 | Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation |
| Q34265484 | Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder |
| Q38543238 | Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder |
| Q38755136 | Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis |
Search more.